ABBV-319

ABBV-319 is a first-in-class, steroid-based antibody-drug conjugate (ADC) developed for the treatment of B-cell malignancies. It consists of an afucosylated CD19-targeting monoclonal antibody conjugated via an alanine-alanine protease-cleavable dipeptide linker to a glucocorticoid receptor modulator (GRM) payload. The drug is engineered to reduce systemic glucocorticoid-associated toxicities while enhancing antitumor efficacy through three distinct mechanisms of action: 1. Antibody-mediated delivery of the GRM payload directly to CD19-expressing cells, inducing apoptosis. 2. Inhibition of CD19 signaling pathways in malignant B cells. 3. Enhanced fragment crystallizable (Fc)-mediated effector function, such as antibody-dependent cellular cytotoxicity (ADCC), due to afucosylation of the antibody backbone. Preclinical studies have shown that ABBV-319’s GRM payload is significantly more potent than standard clinical glucocorticoids like dexamethasone and prednisolone in inducing cell death in glucocorticoid-sensitive B-cell lines[1][2][6]. The drug is currently being evaluated in Phase 1 clinical trials for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL)[3][4][5].